GLP-1R AGONIST COMPOUND AND USE THEREOF

1 . A compound represented by Formula I, or an isotope-labelled compound, a stereoisomer, or a pharmaceutically acceptable salt thereof:

wherein

X 1 , X 2 , and X 3 are independently selected from the group consisting of N and C;

rings A, B, and C are independently selected from the group consisting of C 3-10 cycloalkyl, heterocyclyl, aryl, and heteroaryl;

each R 1 is independently selected from the group consisting of hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, —CN, —NO 2 , —NR A1 R B1 , —OR A1 , —C(O)R A1 , —C(O)OR A1 , —OC(O)R A1 , —C(O)NR A1 R B1 , —NR A1 C(O)R B1 , —OC(O)NR A1 R B1 , —S(O) r A1 , —S(O) 2 OR A1 , —OS(O) 2 R A1 , —NR A1 S(O) r R B1 , —S(O) r NR A1 R B1 , —P(O)R A1 R B1 , and —P(O)(OR A1 )(OR B1 ), wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is unsubstituted or substituted independently with at least one R X1 ;

each R 2 is independently selected from the group consisting of hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, —(CH 2 ) s CF 3 , —CN, —NO 2 , —NR A2 R B2 , —OR A2 , —C(O)R A2 , —C(O)OR A2 , —OC(O)R A2 , —C(O)NR A2 R B2 , —NR A2 C(O)R B2 , —OC(O)NR A2 R B2 , —NR A2 C(O)OR B2 , —S(O) r R A2 , —P(O)R A2 R B2 , —S(O) r NR A2 R B2 , and —P(O)(OR A2 )(OR B2 ), wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is unsubstituted or substituted independently with at least one R X2 ;

each R 3 is independently selected from the group consisting of hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, —CN, —NO 2 , —NR A3 R B3 , —OR A3 , and —C(O)R A3 , wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is unsubstituted or substituted independently with at least one R X3 ; or

two R 3 , together with the atom(s) to which they are attached, form a C 3-10 cycloalkyl or 4- to 12-membered heterocyclyl containing 1, 2, or 3 heteroatoms, wherein the heteroatoms are independently selected from the group consisting of oxygen, sulfur, nitrogen, and phosphorus, and the ring thereof is unsubstituted or substituted independently with 1, 2, or 3 R X3 ;

R 4 is selected from the group consisting of —C(O)OH, heterocyclyl, and heteroaryl;

R 5 is selected from the group consisting of hydrogen and C 1-6 alkyl;

R 6 is selected from the group consisting of hydrogen, halogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, —CN, —NO 2 , —NR A4 R B4 , —OR A4 , and —C(O)R A4 , wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is unsubstituted or substituted independently with at least one R X4 ;

R 9 and R 10 , together with the atom to which they are attached, form a fragment

 and R 7 and R 8 are independently selected from the group consisting of hydrogen, halogen, and C 1-3 alkyl;

ring T′ is selected from the group consisting of C 3-10 cycloalkyl, C 3-8 cycloalkenyl, 3- to 12-membered heterocyclyl, and 5- to 6-membered heteroaryl, and the rings are unsubstituted or substituted independently with 1, 2, or 3 R X ;

“ ” is a single bond or a double bond;

each of R A1 , R A2 , R A3 , R A4 , R B1 , R B2 , R B3 , and R B4 is independently selected from the group consisting of hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, and heteroaryl-C 1-4 alkyl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is unsubstituted or substituted with at least one substituent independently selected from the group consisting of hydroxyl, oxo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, cyano, alkoxy, alkylamino, di(alkyl)amino, haloalkyl, acyl, sulfonyl, sulfonamido, and halogen; or

“R A1 and R B1 ” or “R A2 and R B2 ” or “R A3 and R B3 ”, together with single or multiple atom(s) to which they are attached, form a 4- to 12-membered heterocyclic ring containing 0, 1, or 2 additional heteroatoms independently selected from the group consisting of oxygen, sulfur, nitrogen, and phosphorus, and the ring is unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of hydroxyl, oxo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, cyano, alkoxy, alkylamino, di(alkyl)amino, haloalkyl, acyl, sulfonyl, sulfonamido, and halogen;

each of R X , R X1 , R X2 , R X3 , and R X4 is independently selected from the group consisting of hydroxyl, oxo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, cyano, alkoxy, alkylamino, di(alkyl)amino, haloalkyl, acyl, sulfonyl, sulfonamido, and halogen;

m, n, and p are independently selected from the group consisting of 0, 1, 2, and 3; and

r and s are independently selected from the group consisting of 0, 1, and 2.

2 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring T′ is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and oxocyclobutyl, and the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and oxocyclobutyl are unsubstituted or substituted independently with 1, 2, or 3 R X ;

R X is as defined in claim 1 .

3 . (canceled)

4 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring T′ is selected from the group consisting of oxiranyl, oxetanyl, oxolanyl, oxanyl, aziridinyl, azetidinyl, azinanyl, and thietanyl, and the oxiranyl, oxetanyl, oxolanyl, oxanyl, aziridinyl, azetidinyl, azinanyl, and thietanyl are unsubstituted or substituted independently with 1, 2, or 3 R X ;

R X is as defined in claim 1 .

5 . (canceled)

6 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring T′ is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and C 4-8 cycloalkenyl, and the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and C 4-8 cycloalkenyl are unsubstituted or substituted independently with 1, 2, or 3 R X ;

each R X is independently selected from the group consisting of hydroxyl, oxo, C 1-6 alkyl, C 2-6 alkenyl, alkylamino, —O—C 1-6 alkyl, —O—C 1-6 cycloalkyl, and halogen, or each R X is independently selected from the group consisting of hydroxyl, oxo, C 1-6 alkyl, —O—C 1-6 alkyl, —O—C 1-6 cycloalkyl, and halogen.

7 . (canceled)

8 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring T′ is selected from the group consisting of oxiranyl, oxetanyl, oxolanyl, oxanyl, aziridinyl, azetidinyl, azolidinyl, azinanyl, thietanyl, thiolanyl, and thianyl, and the oxiranyl, oxetanyl, oxolanyl, oxanyl, aziridinyl, azetidinyl, azolidinyl, azinanyl, thietanyl, thiolanyl, and thianyl are unsubstituted or substituted independently with 1, 2, or 3 R X ;

each R X is independently selected from the group consisting of hydroxyl, oxo, C 1-6 alkyl, alkoxy, —C(O)H, —C(O)—C 1-6 alkyl, —C(O)—C 1-6 cycloalkyl, —C(O)—C 1-6 alkyl-C 1-6 alkoxy, —C(O)— haloalkyl, —C(O)—C 1-6 alkoxy, —C(O)—C 1-6 alkylamino, —C(O)-aminoalkyl, —C(O)NH 2 , sulfonyl, and halogen.

9 .- 17 . (canceled)

18 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

X 1 , X 2 , and X 3 are independently selected from the group consisting of N and C, wherein only one is N and the other two are C.

19 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring A is aryl or heteroaryl.

20 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring A is

each R 1 is independently selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 3-6 cycloalkyl, and C 1-4 alkoxy, and m is selected from the group consisting of 1, 2, and 3.

21 . (canceled)

22 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring B is

23 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring B is

each R 2 is independently selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, C 3-6 cycloalkyl, —CH 2 CF 3 , —S(O) 2 NR A2 R B2 , —S(O) 2 R A2 and —P(O)R A2 R B2 ;

each of R A2 and R B2 is independently selected from the group consisting of C 1-4 alkyl and C 3-6 cycloalkyl; and n is 1, 2, or 3.

24 . (canceled)

25 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring C is heterocyclyl or heteroaryl;

each R 3 is independently selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, and C 3-6 cycloalkyl; and p is 0, 1, 2, or 3, and when p≥2, any two R 3 , optionally together with the atom(s) to which they are attached, form a C 3-10 cycloalkyl.

26 . The compound according to claim 25 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring C is

27 . (canceled)

28 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

R 4 is

or R 4 is

29 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

R 5 is hydrogen or C 1-3 alkyl, or R 5 is hydrogen or methyl.

30 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

R 6 is hydrogen or C 1-3 alkyl, or R 6 is methyl.

31 .- 36 . (canceled)

37 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the compound has any one of the following structures:

wherein

 is selected from the group consisting of

 is selected from the group consisting of

is selected from the group consisting of

 is selected from the group consisting of

 is selected from the group consisting of

 is selected from the group consisting of

R 4 is

R 5 is hydrogen or methyl;

R 6 is methyl;

ring T′ is as defined in claim 1 .

38 .- 41 . (canceled)

42 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer or pharmaceutically acceptable salt thereof, wherein

the compound has the following structure:

wherein

 is selected from the group consisting of

 is selected from the group consisting of

R 4 is

R 5 is methyl;

R 6 is methyl;

ring T′ is as defined in claim 1 .

43 . The compound according to claim 42 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring T′ is C 3-6 cycloalkyl, and the ring is unsubstituted or substituted independently with 1, 2, or 3 R X ;

each R X is independently selected from the group consisting of C 1-3 alkyl, vinyl, —O—C 1-3 alkyl, and halogen.

44 .- 45 . (canceled)

46 . The compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the compound has the following structure:

wherein

ring T′ is as defined in claim 1 .

47 . The compound according to claim 46 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein

the ring T′ is C 3-6 cycloalkyl; and the ring is unsubstituted or substituted independently with 1, 2, or 3 R X ;

each R X is independently selected from the group consisting of C 1-3 alkyl, vinyl, —O—C 1-6 alkyl, and halogen.

48 .- 56 . (canceled)

57 . A compound, or an isotope-labelled compound, a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is one of the following compounds:

58 . A pharmaceutical composition, comprising the compound according claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

59 . (canceled)

60 . A method for treating, and/or ameliorating, and/or preventing a disease or condition in a subject in need thereof, the method comprising: administering to the subject an effective amount of the compound according to claim 1 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the disease or condition is responsive to GLP-1R inhibition or is mediated or modulated b GLP-1R.

61 . The method according to claim 60 , wherein

the disease or condition is selected from the group consisting of diabetes, diabetic complications, obesity, impaired glucose tolerance, overweight, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, arrhythmia, cerebral infarction, stroke, liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, dementia, Parkinson's disease, and diabetic nephropathy.

62 . A pharmaceutical composition, comprising the compound according claim 57 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

63 . A method for treating and/or ameliorating and/or preventing a disease or condition in a subject in need thereof, the method comprising: administering to the subject an effective amount of the compound according to claim 57 , or the isotope-labelled compound, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the disease or condition is responsive to GLP-1R inhibition or is mediated or modulated by GLP-1R.

64 . The method according to claim 63 , wherein the disease or condition is selected from the group consisting of diabetes, diabetic complications, obesity, impaired glucose tolerance, overweight, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, arrhythmia, cerebral infarction, stroke, liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, dementia, Parkinson's disease, and diabetic nephropathy.